Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 16/20 | 1.00 |
| ▸ | PGGT1B | P53609 | 11/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | FNTB | P49356 | 14/20 | 0.84 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392871 | 1.00 | FNTA (1.00) | FNTAPGGT1BTDP1FNTBTAS1R3 | |
| SCHEMBL16136630 | 1.00 | FNTA (1.00) | FNTAPGGT1BTDP1FNTBTAS1R3 | |
| Trifluoroacetic Acid SCHEMBL16499777 | 0.94 | FNTA (0.89) | FNTAPGGT1BTDP1FNTBTAS1R3 | |
| Trifluoroacetic Acid SCHEMBL16499780 | 0.94 | FNTA (0.89) | FNTAPGGT1BTDP1FNTBTAS1R3 | |
| Trifluoroacetic Acid SCHEMBL30104219 | 0.94 | FNTA (0.89) | FNTAPGGT1BTDP1FNTBTAS1R3 | |
| SCHEMBL16136644 | 0.91 | FNTA (1.00) | FNTAPGGT1BTDP1FNTB | |
| SCHEMBL1804295 | 0.91 | FNTA (1.00) | FNTAPGGT1BTDP1FNTB | |
| SCHEMBL14169141 | 0.91 | FNTA (0.87) | FNTAPGGT1BTDP1FNTB | |
| SCHEMBL16499927 | 0.91 | FNTA (1.00) | FNTAPGGT1BTDP1FNTB | |
| SCHEMBL25211622 | 0.90 | FNTA (0.81) | FNTAPGGT1BTDP1FNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11382971-B2 | Mevalonate pathway inhibitor as highly-efficient vaccine adjuvant | TSINGHUA UNIVERSITY (CN) | 2022-07-12 | — | — | US | disclosed |
| US-20210008084-A1 | MEVALONATE PATHWAY INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF | TSINGHUA UNIVERSITY (CN) | 2021-01-14 | — | — | US | disclosed |
| US-20190321465-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | TSINGHUA UNIVERSITY (CN) | 2019-10-24 | — | — | US | disclosed |
| US-20120108632-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2011088126-A2 | TREATMENT OF VIRAL INFECTION WITH PRENYLTRANSFERASE INHIBITORS | EIGER BIOPHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| US-20110112053-A1 | PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
| US-20100120851-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120851-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2008080110-A1 | METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR | ALCON, INC. (CH) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153819-A1 | METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20070232675-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | ALCON MANUFACTURING, LTD. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232675-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | ALCON MANUFACTURING, LTD. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070219208-A1 | Methods for Treating Cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112053-A1 | PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATIONS | RHOA, LIPG, KDR | FNTA 161/4885PGGT1B 735/4885TDP1 2726/4885 |
| US-20070232675-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | FNTA, PTAR1, RHOA | FNTA 1/4885PGGT1B 8/4885TDP1 1351/4885 |
| US-20190321465-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | GGPS1, HMGCR, COASY | FNTA 5/4885PGGT1B 251/4885TDP1 3476/4885 |
| US-20100120851-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | FNTA, PTAR1, RHOA | FNTA 1/4885PGGT1B 8/4885TDP1 1351/4885 |
| US-11382971-B2 | Mevalonate pathway inhibitor as highly-efficient vaccine adjuvant | GGPS1, HMGCR, COASY | FNTA 5/4885PGGT1B 247/4885TDP1 3503/4885 |
| US-20210008084-A1 | MEVALONATE PATHWAY INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF | PDCD1, CD274, PDCD5 | FNTA 42/4885PGGT1B 154/4885TDP1 3364/4885 |
| US-20120108632-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | FNTA, PTAR1, RHOA | FNTA 1/4885PGGT1B 8/4885TDP1 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.